Approximately 100,000 cases of human infection with the E. coli O157:H7 organism are reported each year in North America. 2% to 7% of those people develop hemolytic uremic syndrome (HUS), a disease characterized by kidney failure (in recent outbreaks, this percentage has risen to as high as 16%). Five percent of HUS patients die, many of them children and senior citizens, whose kidneys are more sensitive to damage.
In addition to being infected by contaminated food or water, individuals can become infected from E. coli O157:H7 by visiting animal exhibits. Petting zoos, fairs, and agricultural exhibits provide many possible routes of transmission for E. coli. Direct animal contact is the obvious route, but contact with contaminated products (e.g., sawdust, shavings, soiled clothing or shoes) can also lead to human infection.
The E. coli O157:H7 cattle vaccine will be manufactured in the Bioniche production facility in Belleville, Ontario, Canada where a two-year, $25 million expansion is taking place, supported by the Ontario and Canadian governments. Vaccine supply will be limited during this manufacturing expansion period.
About the E. coli O157:H7 Cattle Vaccine
This vaccine received international recognition in September, 2007 by
the Animal Pharm Industry Excellence Awards as the best new veterinary
product for livestock globally. The vaccine has been developed by a
strategic alliance formed in 2000 between the University of British
Columbia (UBC), the Alberta Research Council (ARC), the University of
Saskatchewan's Vaccine & Infectious Disease Organization (VIDO), and
Bioniche, which holds the rights for worldwide commercialization of the
vaccine. The vaccine prevents the E. coli O157:H7 bacteria from attaching
to the intestines of vaccinated cattle, thereby reducing their reproduction
within the animal, and
|SOURCE Bioniche Life Sciences Inc.|
Copyright©2008 PR Newswire.
All rights reserved